X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs GSK PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE GSK PHARMA CADILA HEALTHCARE/
GSK PHARMA
 
P/E (TTM) x 19.5 59.8 32.6% View Chart
P/BV x 4.6 12.0 38.3% View Chart
Dividend Yield % 0.9 2.4 37.1%  

Financials

 CADILA HEALTHCARE   GSK PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
GSK PHARMA
Mar-18
CADILA HEALTHCARE/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs5582,760 20.2%   
Low Rs3622,040 17.7%   
Sales per share (Unadj.) Rs116.3339.0 34.3%  
Earnings per share (Unadj.) Rs17.941.4 43.1%  
Cash flow per share (Unadj.) Rs23.145.9 50.4%  
Dividends per share (Unadj.) Rs3.5035.00 10.0%  
Dividend yield (eoy) %0.81.5 52.2%  
Book value per share (Unadj.) Rs85.4242.9 35.2%  
Shares outstanding (eoy) m1,023.7484.70 1,208.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.07.1 55.8%   
Avg P/E ratio x25.757.9 44.4%  
P/CF ratio (eoy) x19.952.3 38.0%  
Price / Book Value ratio x5.49.9 54.5%  
Dividend payout %19.684.5 23.2%   
Avg Mkt Cap Rs m470,664203,280 231.5%   
No. of employees `00011.8NA-   
Total wages/salary Rs m18,5455,234 354.3%   
Avg. sales/employee Rs Th10,072.7NM-  
Avg. wages/employee Rs Th1,569.1NM-  
Avg. net profit/employee Rs Th1,547.7NM-  
INCOME DATA
Net Sales Rs m119,04928,715 414.6%  
Other income Rs m1,132545 207.5%   
Total revenues Rs m120,18129,260 410.7%   
Gross profit Rs m28,4755,059 562.9%  
Depreciation Rs m5,388380 1,417.9%   
Interest Rs m9112 45,550.0%   
Profit before tax Rs m23,3085,222 446.3%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m5,6441,892 298.3%   
Profit after tax Rs m18,2923,508 521.4%  
Gross profit margin %23.917.6 135.8%  
Effective tax rate %24.236.2 66.8%   
Net profit margin %15.412.2 125.8%  
BALANCE SHEET DATA
Current assets Rs m82,00521,815 375.9%   
Current liabilities Rs m60,72015,999 379.5%   
Net working cap to sales %17.920.3 88.3%  
Current ratio x1.41.4 99.0%  
Inventory Days Days7364 115.0%  
Debtors Days Days9819 526.1%  
Net fixed assets Rs m83,70312,475 671.0%   
Share capital Rs m1,024847 120.9%   
"Free" reserves Rs m86,42119,726 438.1%   
Net worth Rs m87,44520,573 425.0%   
Long term debt Rs m25,5516 425,850.0%   
Total assets Rs m180,65339,475 457.6%  
Interest coverage x26.62,612.0 1.0%   
Debt to equity ratio x0.30 100,190.2%  
Sales to assets ratio x0.70.7 90.6%   
Return on assets %10.68.9 119.5%  
Return on equity %20.917.1 122.7%  
Return on capital %22.026.2 83.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,683564 7,567.9%   
Fx outflow Rs m11,2427,429 151.3%   
Net fx Rs m31,441-6,865 -458.0%   
CASH FLOW
From Operations Rs m9,1934,728 194.4%  
From Investments Rs m-9,737-1,042 934.5%  
From Financial Activity Rs m515-3,066 -16.8%  
Net Cashflow Rs m-29620 -4.7%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 8.3 10.2 81.4%  
FIIs % 5.9 23.8 24.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 15.4 71.4%  
Shareholders   44,069 102,036 43.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   AUROBINDO PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK LTD  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Related Views on News

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Up 274.4% (Quarterly Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

For the quarter ended June 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (up 274.4% YoY). Sales on the other hand came in at Rs 29 bn (up 29.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Sep 25, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - AJANTA PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS